Clinical guidelines recommended performing multiparametric magnetic resonance imaging (mpMRI) and fusion targeting any mpMRI lesions in the repeat-biopsy setting. However, its role in biopsy-ïve men remained controversial. We synthesized current evidence based on well-designed randomized controlled trials (RCTs) to investigate the role of prebiopsy mpMRI and MRI/TRUS fusion targeted biopsy (TB) for prostate cancer (PCa) diagnosis in biopsy-na ave men.
INTRODUCTION AND OBJECTIVES:
Clinical guidelines recommended performing multiparametric magnetic resonance imaging (mpMRI) and fusion targeting any mpMRI lesions in the repeat-biopsy setting. However, its role in biopsy-ïve men remained controversial. We synthesized current evidence based on well-designed randomized controlled trials (RCTs) to investigate the role of prebiopsy mpMRI and MRI/TRUS fusion targeted biopsy (TB) for prostate cancer (PCa) diagnosis in biopsy-na ave men.
METHODS: A systematic review of PubMed (Medline), Embase, Ovid and the Cochrane Library up to 1st October 2018 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. The statistical analyses were performed with Revman 5.3. We compared the diagnostic accuracy between the intervention group (using prebiopsy mpMRI to select patients for TB) and the control group (standard biopsy regardless of MRI results) by calculating the risk ratio (RR) with 95% confidence intervals (CIs) of overall PCa and clinically significant PCa (csPCa) detection rates (DRs). Subgroup analysis was performed to highlight the independent role of SB and MRI/TRUS fusion TB by stratifying patients of different biopsy approach.
RESULTS: Six RCTs with 2187 participants were evaluated. Pooled analysis revealed slight higher overall PCa DRs of 62.7% (687/ 1095) in the intervention group compared with that of 41.3% (451/1092) in the control group (RR 1.40, 95% CI: 1.00-1.95) [ Figure 1 ]. And there was a trend favoring the use mpMRI before biopsy which detected more csPCa (42.8%, 206/481) compared with SB only in the control group (31.6%, 152/481) (RR 1.36, 95% CI: 0.95-1.95) [ Figure 2 ]. Further analysis revealed positive prebiopsy mpMRI with MRI/fusion TB detected more csPCa (52.9%, 193/365) in the intervention group compared with SB only without any mpMRI in the control group (31.6%, 152/481) (RR 1.64, 95% CI 1.06-2.52) [ Figure 3 ]. However, SB helped detect missed PCa for patients of negative mpMRI (23.5%, 20/85) and nearly half of the tumors were clinically significant.
CONCLUSIONS: The use of prebiopsy mpMRI may help improve overall PCa and csPCa DRs in biopsy-na ave men. However, SB may play a role in detecting missed PCa for patients of negative mpMRI.
Source of Funding: none

MP30-02 ANALYSIS OF CLINICAL AND ONCOLOGICAL FOLLOW-UP AFTER NEGATIVE MRI-TRUS FUSION BIOPSY OF THE PROSTATE
Nicolas von Landenberg*, Joachim Noldus, Julian Hanske, Sebastian Berg, Marko Brock, Herne, Germany INTRODUCTION AND OBJECTIVES: The risk of occult prostate carcinoma (PCa) after negative MRI-TRUS fusion biopsy (F-Bx) is unknown till today. To determine the false-negative predictive value, a cohort was examined for later tumor detection. Furthermore, as part of the follow-up (FU), biopsy-specific complications were collected.
METHODS: Between 12/12 and 11/16, 491 patients with suspected PCa and suspicious MRI findings underwent transrectal F-Bx at our institution. Each biopsy contained 12 systematic and a set of 2 targeted cores out of suspicious MRI lesions. Patients with benign pathologically results (n [ 191) were eligible for our follow-up survey. Patient characteristics (PSA, prostate volume, number of prebiopsies, age, PI-RADS score) were correlated to subsequent findings of newly detected PCa of further examinations. Complications were classified according to Clavien Dindo Classification (CDC). Statistical analyses were conducted (chi2, Kruskal-Wallis, Mann-Whitney U test).
RESULTS: A complete FU was available for 176 (92.2%) of 191 patients with negative F-Bx (10.2% first biopsy, 89.8% re-biopsy). Median FU range was 31 (IQR: 17-39) months. At the time of F-Bx median age was 63 (IQR: 58-69) years, median PSA was 9.1 (IQR: 6.9-12.7) ng/ml and median prostate volume was 45 (IQR: 38.5-51.8) ml for patients with newly detected PCa. MRI lesions were divided into PI-RADS score of <[3 (14.3%), 4 (57.1%) or 5 (28.6%). Secondary PCa was found during FU in 14 (7.95%) of 176 patients and allocated to Gleason Score <[6, 7 and 8 in 50%, 42.9% and 7.1%, respectively. Significant risk-factors for secondary PCa were PSA density and prostate volume (p<0.05).
Main complications were e.g. hematuria (34.9%, CDC1), hematospermia (29.6%, CDC1) or urosepsis (1.1%, CDC3a).
CONCLUSIONS: Despite negative MRI-TRUS fusion biopsy, patients should continue to be monitored as there is still a 8% risk of developing PCa over the time.
